AdvaMed Releases Technical Performance and Safety Bulletin on “Remote Device Operations: Common Challenges and Mitigation Strategies”

WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device manufacturers, and IT teams navigate the complex landscape of remotely managing medical devices.Continue reading

Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

  • Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs
  • Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S.
  • Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology
  • Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today

Continue reading

C-Path Names Colin Hill to Board of Directors

TUCSON, Ariz., Sept. 30, 2025 — Critical Path Institute® (C-Path) today announced the election of Colin Hill, M.S., to its Board of Directors. Hill brings deep experience at the intersection of artificial intelligence, drug development, and translational acceleration. The appointment will further strengthen C-Path’s Board of Directors’ commitment to provide optimal strategic support to the organization’s growth in advancing drug development through collaboration.Continue reading

PhRMA Announces Major Actions as Part of Industry’s Commitment to American Patients and Workers

WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers. 

PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources. Continue reading

Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals

President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759Continue reading